Last reviewed · How we verify
Wangbi granules simulant
Wangbi granules simulant is a Small molecule drug developed by China-Japan Friendship Hospital. It is currently FDA-approved.
At a glance
| Generic name | Wangbi granules simulant |
|---|---|
| Sponsor | China-Japan Friendship Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Wangbi granules simulant CI brief — competitive landscape report
- Wangbi granules simulant updates RSS · CI watch RSS
- China-Japan Friendship Hospital portfolio CI
Frequently asked questions about Wangbi granules simulant
What is Wangbi granules simulant?
Wangbi granules simulant is a Small molecule drug developed by China-Japan Friendship Hospital.
Who makes Wangbi granules simulant?
Wangbi granules simulant is developed and marketed by China-Japan Friendship Hospital (see full China-Japan Friendship Hospital pipeline at /company/china-japan-friendship-hospital).
What development phase is Wangbi granules simulant in?
Wangbi granules simulant is FDA-approved (marketed).
Related
- Manufacturer: China-Japan Friendship Hospital — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing